otlertuzumab

Home
Ligands
otlertuzumab

GtoPdb Ligand ID: 9951

Synonyms: CD37-SMIP [8] | TRU-016 | TRU016

Comment: Otlertuzumab (TRU-016) is a monospecific, humanized anti-CD37 antibody-like protein that is being investigated as a clinical therapeutic for various form of lymphoma [4,6-7]. Otlertuzumab was developed using Aptevo's modular ADAPTIR^TM platform.

Immunopharmacology Comments
CD37 is an immuno-oncology target that is being evaluated for the treatment of B cell malignancies, including non-Hodgkin lymphoma, and CLL [6].

Immunopharmacology Comments

CD37 is an immuno-oncology target that is being evaluated for the treatment of B cell malignancies, including non-Hodgkin lymphoma, and CLL [6].

Immunopharmacology Disease
Disease	X-Refs	Comment	References
non-Hodgkin lymphoma	Disease Ontology: DOID:0060060 OMIM: 605027	Phase 1 clinical candidate for NHL- see NCT00614042 and NCT01317901.
B-cell lymphoma	Disease Ontology: DOID:707	Phase 1b clinical candidate for indolent B-cell small lymphocytic lymphoma.	2
Chronic lymphocytic leukemia	Disease Ontology: DOID:1040 OMIM: 151400 Orphanet: ORPHA67038	Phase 1 clinical candidate for CLL- see NCT01644253.	1